| Literature DB >> 7669259 |
D M Lang1.
Abstract
Studies have demonstrated greater hazards associated with anaphylaxis in patients receiving beta-blockers. Serious anaphylaxis is more frequent. Evidence suggests this occurs via modulation of adenylate cyclase, which can influence release of anaphylactogenic mediators. Treatment of anaphylaxis in patients exposed to beta-blockers is complicated because therapeutic administration of epinephrine (adrenaline) may be ineffective or promote undesired alpha-adrenergic and vagotonic effects. Risk reduction efforts should be considered for patients receiving beta-blockers who are prone to experience anaphylaxis.Entities:
Mesh:
Substances:
Year: 1995 PMID: 7669259 DOI: 10.2165/00002018-199512050-00002
Source DB: PubMed Journal: Drug Saf ISSN: 0114-5916 Impact factor: 5.606